PMID- 24966688
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140626
LR  - 20211021
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 7
DP  - 2014
TI  - HCA519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular 
      carcinoma.
PG  - 1061-70
LID - 10.2147/OTT.S61442 [doi]
AB  - BACKGROUND: Immunotherapy for human hepatocellular cancer (HCC) is slowly making 
      progress towards treating these fatal cancers. The identification of new antigens 
      can improve this approach. We describe a possible new antigen, hepatocellular 
      carcinoma-associated antigen-519/targeting protein for Xklp-2 (HCA519/TPX2), for 
      HCC that might be beneficial for T-cell specific HCC immunotherapy. METHODS: HCC 
      was studied for the expression for 15 tumor-associated antigens considered useful 
      for immunotherapy within three HCC cell lines (HepG2, Hep3B, and PLC/PRF/5), 
      lymphocytes, non-cancerous livers, and clinical HCC. The expression of tumor 
      antigenic precursor proteins (TAPPs) messenger RNA was first screened by reverse 
      transcriptase quantitative real-time polymerase chain reaction. RESULTS: Four 
      antigens (alpha fetoprotein, aspartyl/asparaginyl beta-hydroxylase, glypican-3 and 
      HCA519/TPX2) proved to be the best expressed TAPPs within the HCC specimens by 
      molecular analyses. HCA519/TPX2 was detected by intracellular cell flow cytometry 
      within HCC cell lines by using a specific antibody towards this TAPP. This 
      antibody also detected the protein within primary HCCs. We synthesized two 
      HCA519/TPX2 peptides (HCA519464-472 and HCA519351-359) which can bind to human 
      leukocyte antigen (HLA)-A*0201. Dendritic cells pulsed with these peptides 
      stimulated cytolytic T lymphocytes (CTLs). These killer T-cells lysed HLA-A*0201+ 
      T2 cells exogenously loaded with the correct specific peptide. The CTLs killed 
      HepG2 (HLA-A2+ and HCA519+), but not the Hep3B and PLC/PRF/5 cell lines, which 
      are HCA519+ but HLA-A2-negative. In silico analysis reveals that HCA519/TPX2 has 
      the inherent ability to bind to a very wide variety of HLA antigens. CONCLUSION: 
      HCA519/TPX2 is a viable immunotarget that should be further investigated within 
      HCC patients.
FAU - Aref, Ahmed M
AU  - Aref AM
AD  - Biological Science Department, Modern Sciences and Arts University, Faculty of 
      Dentistry, Cairo, Egypt ; Southern California Institute for Research and 
      Education, Veterans Affairs Medical Center, Long Beach, CA, USA ; Research Health 
      Care Group, Veterans Affairs Medical Center Long Beach, CA, USA.
FAU - Hoa, Neil T
AU  - Hoa NT
AD  - Research Health Care Group, Veterans Affairs Medical Center Long Beach, CA, USA.
FAU - Ge, Lisheng
AU  - Ge L
AD  - Research Health Care Group, Veterans Affairs Medical Center Long Beach, CA, USA.
FAU - Agrawal, Anshu
AU  - Agrawal A
AD  - Department of Medicine, Division of Basic and Clinical Immunology, University of 
      California, Irvine, CA, USA.
FAU - Dacosta-Iyer, Maria
AU  - Dacosta-Iyer M
AD  - Pathology and Laboratory Medicine Department, Veterans Affairs Medical Center 
      Long Beach, CA, USA ; Department of Pathology and Laboratory Medicine, University 
      of California, Irvine, CA, USA.
FAU - Lambrecht, Nils
AU  - Lambrecht N
AD  - Pathology and Laboratory Medicine Department, Veterans Affairs Medical Center 
      Long Beach, CA, USA ; Department of Pathology and Laboratory Medicine, University 
      of California, Irvine, CA, USA.
FAU - Ouyang, Yi
AU  - Ouyang Y
AD  - Pathology and Laboratory Medicine Department, Veterans Affairs Medical Center 
      Long Beach, CA, USA ; Department of Pathology and Laboratory Medicine, University 
      of California, Irvine, CA, USA.
FAU - Cornforth, Andrew N
AU  - Cornforth AN
AD  - California Stem Cells, Inc., CA, USA.
FAU - Jadus, Martin R
AU  - Jadus MR
AD  - Pathology and Laboratory Medicine Department, Veterans Affairs Medical Center 
      Long Beach, CA, USA ; Department of Pathology and Laboratory Medicine, University 
      of California, Irvine, CA, USA ; Neuro-Oncology Program, Chao Comprehensive 
      Cancer Center, University of California, Irvine, CA, USA.
LA  - eng
GR  - P30 CA062203/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20140613
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4063820
OTO - NOTNLM
OT  - HCA519/TPX2
OT  - HLA-A2
OT  - cytolytic T-cells
OT  - tumor immunity
EDAT- 2014/06/27 06:00
MHDA- 2014/06/27 06:01
PMCR- 2014/06/13
CRDT- 2014/06/27 06:00
PHST- 2014/06/27 06:00 [entrez]
PHST- 2014/06/27 06:00 [pubmed]
PHST- 2014/06/27 06:01 [medline]
PHST- 2014/06/13 00:00 [pmc-release]
AID - ott-7-1061 [pii]
AID - 10.2147/OTT.S61442 [doi]
PST - epublish
SO  - Onco Targets Ther. 2014 Jun 13;7:1061-70. doi: 10.2147/OTT.S61442. eCollection 
      2014.